Which has higher valuation and earnings, GSK or MRK?

Merck & Co., Inc. has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.30 $7.54B $3.20 15.33 Merck & Co., Inc. $65.01B 5.53 $18.25B $1.25 116.53

Is GSK or MRK more profitable?

GSK has a net margin of 14.56% compared to Merck & Co., Inc.'s net margin of 4.77%. GSK's return on equity of 43.23% beat Merck & Co., Inc.'s return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Merck & Co., Inc. 4.77% 16.73% 6.13%

Does the media favor GSK or MRK?

In the previous week, Merck & Co., Inc. had 44 more articles in the media than GSK. MarketBeat recorded 67 mentions for Merck & Co., Inc. and 23 mentions for GSK. Merck & Co., Inc.'s average media sentiment score of 0.83 beat GSK's score of 0.12 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Merck & Co., Inc. 39 Very Positive mention(s) 6 Positive mention(s) 11 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Positive

Do analysts prefer GSK or NVS?

GSK currently has a consensus price target of $55.33, suggesting a potential upside of 12.79%. Novartis has a consensus price target of $145.60, suggesting a potential downside of 3.15%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Novartis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 3 Sell rating(s) 12 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.05 Novartis 2 Sell rating(s) 12 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better earnings and valuation, GSK or NVS?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.30 $7.54B $3.20 15.33 Novartis $54.53B 5.26 $13.98B $6.63 22.68

Is GSK or NVS more profitable?

Novartis has a net margin of 23.29% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Novartis 23.29% 38.56% 14.47%

Does the media favor GSK or NVS?

In the previous week, GSK had 14 more articles in the media than Novartis. MarketBeat recorded 23 mentions for GSK and 9 mentions for Novartis. Novartis' average media sentiment score of 0.80 beat GSK's score of 0.12 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Novartis 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GSK or AZN?

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.30 $7.54B $3.20 15.33 Astrazeneca $58.74B 4.40 $10.23B $6.69 24.91

Is GSK or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Astrazeneca 17.02% 31.45% 13.20%

Does the media refer more to GSK or AZN?

In the previous week, Astrazeneca had 13 more articles in the media than GSK. MarketBeat recorded 36 mentions for Astrazeneca and 23 mentions for GSK. Astrazeneca's average media sentiment score of 0.63 beat GSK's score of 0.12 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Astrazeneca 16 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better earnings & valuation, GSK or NVO?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.30 $7.54B $3.20 15.33 Novo Nordisk A/S $46.80B 3.74 $15.51B $4.09 9.59

Is GSK or NVO more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to GSK's net margin of 14.56%. Novo Nordisk A/S's return on equity of 58.61% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Novo Nordisk A/S 35.36% 58.61% 20.91%

Does the media favor GSK or NVO?

In the previous week, GSK had 7 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 23 mentions for GSK and 16 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 0.49 beat GSK's score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Novo Nordisk A/S 8 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, GSK or PFE?

Pfizer has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.30 $7.54B $3.20 15.33 Pfizer $62.58B 2.68 $7.77B $0.76 38.77

Is GSK or PFE more profitable?

GSK has a net margin of 14.56% compared to Pfizer's net margin of 6.80%. GSK's return on equity of 43.23% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Pfizer 6.80% 19.63% 8.46%

Does the media favor GSK or PFE?

In the previous week, Pfizer had 52 more articles in the media than GSK. MarketBeat recorded 75 mentions for Pfizer and 23 mentions for GSK. Pfizer's average media sentiment score of 0.51 beat GSK's score of 0.12 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 30 Very Positive mention(s) 8 Positive mention(s) 25 Neutral mention(s) 7 Negative mention(s) 2 Very Negative mention(s) Positive

GSK (GSK) Competitors

$49.06 +1.19 (+2.48%)

Closing price 10/15/2026 03:59 PM Eastern

Extended Trading

$49.33 +0.27 (+0.56%)

As of 07:08 AM Eastern

Compare

GSK vs. MRK, NVS, AZN, NVO, and PFE

Should you buy GSK stock or one of its competitors? GSK's main competitors and comparable companies include Merck & Co., Inc. (MRK), Novartis (NVS), Astrazeneca (AZN), Novo Nordisk A/S (NVO), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GSK compare to Merck & Co., Inc.?

GSK (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Merck & Co., Inc. has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.30	$7.54B	$3.20	15.33
Merck & Co., Inc.	$65.01B	5.53	$18.25B	$1.25	116.53

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.6%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.3%. GSK pays out 55.3% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 14 consecutive years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Merck & Co., Inc. had 44 more articles in the media than GSK. MarketBeat recorded 67 mentions for Merck & Co., Inc. and 23 mentions for GSK. Merck & Co., Inc.'s average media sentiment score of 0.83 beat GSK's score of 0.12 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Merck & Co., Inc.	39 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Positive

GSK has a net margin of 14.56% compared to Merck & Co., Inc.'s net margin of 4.77%. GSK's return on equity of 43.23% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Merck & Co., Inc.	4.77%	16.73%	6.13%

GSK currently has a consensus target price of $55.33, suggesting a potential upside of 12.79%. Merck & Co., Inc. has a consensus target price of $151.92, suggesting a potential upside of 4.30%. Given GSK's higher possible upside, research analysts plainly believe GSK is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.05
Merck & Co., Inc.	0 Sell rating(s)	10 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.63

15.7% of GSK shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GSK has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

Summary

Merck & Co., Inc. beats GSK on 10 of the 19 factors compared between the two stocks.

How does GSK compare to Novartis?

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

GSK currently has a consensus price target of $55.33, suggesting a potential upside of 12.79%. Novartis has a consensus price target of $145.60, suggesting a potential downside of 3.15%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.05
Novartis	2 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, GSK had 14 more articles in the media than Novartis. MarketBeat recorded 23 mentions for GSK and 9 mentions for Novartis. Novartis' average media sentiment score of 0.80 beat GSK's score of 0.12 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novartis	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.30	$7.54B	$3.20	15.33
Novartis	$54.53B	5.26	$13.98B	$6.63	22.68

Novartis has a net margin of 23.29% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Novartis	23.29%	38.56%	14.47%

GSK has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Novartis has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

15.7% of GSK shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.6%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. GSK pays out 55.3% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novartis beats GSK on 12 of the 18 factors compared between the two stocks.

How does GSK compare to Astrazeneca?

GSK (NYSE:GSK) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

GSK presently has a consensus target price of $55.33, suggesting a potential upside of 12.79%. Astrazeneca has a consensus target price of $206.67, suggesting a potential upside of 24.01%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.05
Astrazeneca	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Astrazeneca had 13 more articles in the media than GSK. MarketBeat recorded 36 mentions for Astrazeneca and 23 mentions for GSK. Astrazeneca's average media sentiment score of 0.63 beat GSK's score of 0.12 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Astrazeneca	16 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive

GSK has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

15.7% of GSK shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.6%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. GSK pays out 55.3% of its earnings in the form of a dividend. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Astrazeneca has a net margin of 17.02% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Astrazeneca	17.02%	31.45%	13.20%

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.30	$7.54B	$3.20	15.33
Astrazeneca	$58.74B	4.40	$10.23B	$6.69	24.91

Summary

Astrazeneca beats GSK on 13 of the 18 factors compared between the two stocks.

How does GSK compare to Novo Nordisk A/S?

GSK (NYSE:GSK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

15.7% of GSK shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

GSK has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, GSK had 7 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 23 mentions for GSK and 16 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 0.49 beat GSK's score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novo Nordisk A/S	8 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.6%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.1%. GSK pays out 55.3% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK presently has a consensus target price of $55.33, indicating a potential upside of 12.79%. Novo Nordisk A/S has a consensus target price of $59.44, indicating a potential upside of 51.54%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.05
Novo Nordisk A/S	5 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.00

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.30	$7.54B	$3.20	15.33
Novo Nordisk A/S	$46.80B	3.74	$15.51B	$4.09	9.59

Novo Nordisk A/S has a net margin of 35.36% compared to GSK's net margin of 14.56%. Novo Nordisk A/S's return on equity of 58.61% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Novo Nordisk A/S	35.36%	58.61%	20.91%

Summary

Novo Nordisk A/S beats GSK on 12 of the 18 factors compared between the two stocks.

How does GSK compare to Pfizer?

GSK (NYSE:GSK) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.6%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 5.8%. GSK pays out 55.3% of its earnings in the form of a dividend. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

GSK has a net margin of 14.56% compared to Pfizer's net margin of 6.80%. GSK's return on equity of 43.23% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Pfizer	6.80%	19.63%	8.46%

Pfizer has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.30	$7.54B	$3.20	15.33
Pfizer	$62.58B	2.68	$7.77B	$0.76	38.77

15.7% of GSK shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GSK has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

GSK currently has a consensus price target of $55.33, suggesting a potential upside of 12.79%. Pfizer has a consensus price target of $28.72, suggesting a potential downside of 2.52%. Given GSK's higher possible upside, equities analysts clearly believe GSK is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.05
Pfizer	2 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Pfizer had 52 more articles in the media than GSK. MarketBeat recorded 75 mentions for Pfizer and 23 mentions for GSK. Pfizer's average media sentiment score of 0.51 beat GSK's score of 0.12 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	30 Very Positive mention(s)	8 Positive mention(s)	25 Neutral mention(s)	7 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Pfizer beats GSK on 10 of the 19 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$96.83B	$12.46B	$7.31B	$22.98B
Dividend Yield	3.70%	2.62%	2.51%	3.72%
P/E Ratio	15.34	653.19	213.39	23.47
Price / Sales	2.30	754.02	580.95	13.64
Price / Cash	7.97	83.43	76.19	35.33
Price / Book	4.75	9.33	10.42	4.72
Net Income	$7.54B	$2.84B	$3.50B	$1.07B
7 Day Performance	5.51%	-3.78%	-3.33%	-0.26%
1 Month Performance	-2.43%	-6.96%	-6.59%	-2.04%
1 Year Performance	12.03%	-4.59%	2.69%	7.05%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	3.5052 of 5 stars	$49.06 +2.5%	$55.33 +12.8%	+12.0%	$96.83B	$43.07B	15.34	66,841	Trending News Dividend Cut Gap Up
MRK Merck & Co., Inc.	4.6105 of 5 stars	$141.97 -2.4%	$151.92 +7.0%	+73.2%	$358.85B	$65.01B	113.58	75,000	Trending News Analyst Revision
NVS Novartis	2.9003 of 5 stars	$142.43 -1.0%	$145.60 +2.2%	+15.7%	$274.47B	$54.53B	21.48	75,267	Analyst Revision Gap Up
AZN Astrazeneca	4.799 of 5 stars	$155.93 -1.5%	$206.67 +32.5%	-1.8%	$245.56B	$58.74B	16.31	96,100	Trending News Analyst Upgrade Options Volume Analyst Revision Gap Up
NVO Novo Nordisk A/S	4.0795 of 5 stars	$38.04 -1.4%	$59.44 +56.3%	-30.8%	$172.26B	$46.80B	9.30	69,505	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GSK) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors

GSK vs. MRK, NVS, AZN, NVO, and PFE

How does GSK compare to Merck & Co., Inc.?

Summary

How does GSK compare to Novartis?

Summary

How does GSK compare to Astrazeneca?

Summary

How does GSK compare to Novo Nordisk A/S?

Summary

How does GSK compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK vs. The Competition

GSK Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GSK (GSK) Competitors

GSK vs. MRK, NVS, AZN, NVO, and PFE

How does GSK compare to Merck & Co., Inc.?

Which has higher valuation and earnings, GSK or MRK?

Is GSK or MRK a better dividend stock?

Does the media favor GSK or MRK?

Is GSK or MRK more profitable?

Do analysts prefer GSK or MRK?

Do institutionals & insiders hold more shares of GSK or MRK?

Which has more risk & volatility, GSK or MRK?

Summary

How does GSK compare to Novartis?

Do analysts prefer GSK or NVS?

Does the media favor GSK or NVS?

Which has better earnings and valuation, GSK or NVS?

Is GSK or NVS more profitable?

Which has more volatility & risk, GSK or NVS?

Do insiders & institutionals have more ownership in GSK or NVS?

Is GSK or NVS a better dividend stock?

Summary

How does GSK compare to Astrazeneca?

Do analysts prefer GSK or AZN?

Does the media refer more to GSK or AZN?

Which has more volatility & risk, GSK or AZN?

Do institutionals and insiders believe in GSK or AZN?

Is GSK or AZN a better dividend stock?

Is GSK or AZN more profitable?

Which has stronger earnings & valuation, GSK or AZN?

Summary

How does GSK compare to Novo Nordisk A/S?

Do institutionals & insiders have more ownership in GSK or NVO?

Which has more risk & volatility, GSK or NVO?

Does the media favor GSK or NVO?

Is GSK or NVO a better dividend stock?

Do analysts recommend GSK or NVO?

Which has better earnings & valuation, GSK or NVO?

Is GSK or NVO more profitable?

Summary

How does GSK compare to Pfizer?

Is GSK or PFE a better dividend stock?

Is GSK or PFE more profitable?

Which has stronger valuation and earnings, GSK or PFE?

Do insiders & institutionals believe in GSK or PFE?

Which has more volatility & risk, GSK or PFE?

Do analysts recommend GSK or PFE?

Does the media favor GSK or PFE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK vs. The Competition

GSK Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools